| Literature DB >> 19724914 |
Stefan Buchholz1, Stephan Seitz, Andrew V Schally, Jörg B Engel, Ferenc G Rick, Luca Szalontay, Florian Hohla, Awtar Krishan, Andrea Papadia, Timo Gaiser, Gero Brockhoff, Olaf Ortmann, Klaus Diedrich, Frank Köster.
Abstract
The aim of the present study was to evaluate the expression of receptors for luteinizing hormone-releasing hormone (LHRH) in human specimens of triple-negative breast cancers (TNBC). In addition, we used in vitro and in vivo models of TNBC to investigate if these receptors are suitable targets for the treatment with the LHRH antagonist cetrorelix. Receptors for LHRH were expressed in all tumor samples and in the TNBC cell lines HCC1806 and HCC1937. The proliferation of both TNBC cell lines was significantly inhibited in vitro by 1 microM cetrorelix. Injections of 3 mg cetrorelix on day 1 and 21 resulted in a significant growth inhibition of HCC1806 tumors xenografted into nude mice. Tumors of mice treated with cetrorelix expressed less mRNA for EGFR and HER3 receptors than untreated tumors. After treatment of cells with Cetrorelix a flow cytometric analysis of the cell cycle revealed a decrease in S-phase. Given the low toxicity and clinical availability of cetrorelix, this peptide antagonist should be considered for phase II studies in patients with advanced TNBC.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19724914 DOI： 10.3892/ijo_00000391
Source DB: PubMed Journal: Int J Oncol ISSN： 1019-6439 Impact factor: 5.650